Sign in
CERS Stock Price, Chart, Stats & News
Cerus Corporation
Save
543.00M
Market cap
–
Current P/E
–
Forward P/E
CERS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 54.47% |
Operating margin | -4.21% |
Pretax margin | -7.41% |
Net margin | -7.58% |
Effective tax rate | -2.32% |
ROA | -7.04% |
ROE | -26.42% |
D/E | 1.51x |
Interest coverage ratio | -1.04x |
CERS valuation
P/E | – |
P/S | 1.66x |
P/B | 5.28x |
P/CF | 70.14x |
P/FCF | 308.72x |
P/OCF | 70.14x |
PEG | -8.24x |
EV multiple | -35.05x |
About
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Similar securities
Based on sector and market capitalization
Report issue